KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest Expenses: 2011-2023

Historic Interest Expenses for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Jun 2023 value amounting to $910,000.

  • Supernus Pharmaceuticals' Interest Expenses fell 49.72% to $910,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $5.7 million, marking a year-over-year decrease of 63.28%. This contributed to the annual value of $2.4 million for FY2023, which is 65.84% down from last year.
  • Supernus Pharmaceuticals' Interest Expenses amounted to $910,000 in Q2 2023, which was down 39.53% from $1.5 million recorded in Q1 2023.
  • Supernus Pharmaceuticals' 5-year Interest Expenses high stood at $6.1 million for Q1 2021, and its period low was $910,000 during Q2 2023.
  • Moreover, its 3-year median value for Interest Expenses was $1.9 million (2022), whereas its average is $3.3 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Interest Expenses surged by 718.69% in 2019 and then slumped by 73.14% in 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Interest Expenses (Quarterly) stood at $5.8 million in 2019, then grew by 5.52% to $6.1 million in 2020, then dropped by 2.66% to $5.9 million in 2021, then slumped by 73.14% to $1.6 million in 2022, then crashed by 49.72% to $910,000 in 2023.
  • Its last three reported values are $910,000 in Q2 2023, $1.5 million for Q1 2023, and $1.6 million during Q4 2022.